Certara, which was recently acquired by a global private equity fund for $850m, is a model-informed drug development and regulatory science company. Its D360 platform is a self-service data access, integration, and visualization solution.
The new product, D360 Partner, was developed in response to client requests, according to Certara, and provides external collaborators, such as contract research organizations (CROs), access to project-specific sponsor queries and data views.
Additionally, a management system allows partners to be added and removed with changing projects.
“D360 Partner allows security to be applied at the project or data level by a sponsor,” David Munro, president, Phoenix Technologies at Certara, told Outsourcing-Pharma.com. “Once established, an outside research partner can access either an on-premises or cloud-enabled installation of D360 in a secure manner that can provide real-time data access and analysis.”
Munro said that as collaborations and partnerships continue to expand in the drug development space, the company continues to make investments in solutions that enable its customers to work together better.
“D360 Partner is one investment ongoing at Certara for enabling externalizations, but it also provides common key features that are part of our current and future collaboration initiatives,” he explained.
“While the majority of new drugs are still commercialized by large pharma, the majority of the original drug asset is developed by either an academic organization or an emerging biopharma company,” Munro added. “As Certara provides solutions to both sponsors and outside partners already, we are in a unique position to foster those collaborations with technology and scientific offerings.”